NCT06739928

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

A Safety and Efficacy Evaluation Study of Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Guangzhou Institute of Respiratory Disease · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is a prospective, randomized, parallel, multicenter phase II study aimed at evaluating the efficacy and safety of irinotecan liposome (II) or etoposide combined with adebrelimab and carboplatin as first-line treatment for extensive stage small cell lung cancer. The primary endpoint of the study was the 1-year overall survival rate.

Conditions

• Small Cell Lung Cancer Extensive Stage

Interventions

Type	Name	Description
DRUG	Irinotecan liposome (II) combined with adebrelimab and carboplatin	Irinotecan liposome (II) + adebrelimab + carboplatin
DRUG	etoposide combined with adebrelimab and carboplatin	etoposide + adebrelimab + carboplatin

Timeline

• Start date: 2025-01-01
• Primary completion: 2026-06-30
• Completion: 2027-12-30
• First posted: 2024-12-18
• Last updated: 2024-12-18

Locations

1 site across 1 country: China